Jeffrey del Carmen - 11 Nov 2022 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Commercial Officer
Signature
/s/ Jeffrey Del Carmen
Issuer symbol
CPRX
Transactions as of
11 Nov 2022
Net transactions value
-$1,855,584
Form type
4
Filing time
15 Nov 2022, 16:00:21 UTC
Previous filing
22 Aug 2022
Next filing
29 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $343,200 +120,000 $2.86* 120,000 11 Nov 2022 Direct
transaction CPRX Common stock, par value $0.001 per share Sale $1,947,360 -120,000 -100% $16.23 0 11 Nov 2022 Direct F2
transaction CPRX Common stock, par value $0.001 per share Options Exercise $42,598 +19,017 $2.24* 19,017 11 Nov 2022 Direct
transaction CPRX Common stock, par value $0.001 per share Sale $294,022 -19,017 -100% $15.46 0 11 Nov 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -120,000 -16% $0.000000 627,000 11 Nov 2022 Common Stock 120,000 $2.86 Direct F4
transaction CPRX Options to purchase common stock Options Exercise $0 -19,017 -3% $0.000000 607,983 11 Nov 2022 Common Stock 19,017 $2.24 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold for personal reasons and does not relate to any disagreements with the Company. Mr. Del Carmen remains an officer of the Company.
F2 Shares were sold in various lots from $15.87 to $16.44 per share. The price listed represents a weighted average price for the shares sold.
F3 Shares were sold in various lots from $15.25 to $15.78 per share. The price listed represents a weighted average price for the shares sold.
F4 Options vested in four annual tranches beginning on August 6, 2019.
F5 Options vested in three annual tranches beginning on December 19, 2019.